NCT04348747 2026-02-12
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
Clinical Trials
4 trialsNCT03449238 2025-04-24
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT05255666 2023-07-11
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Washington University School of Medicine
Phase 2 Withdrawn
NCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn